Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene wins HPV (human papillomavirus) deal extension with Quest:

This article was originally published in Clinica

Executive Summary

Gaithersburg, Maryland-based molecular diagnostics company Digene is to supply diagnostic testing service provider Quest Diagnostics with products related to human papillomavirus (HPV) testing for an additional four years. The new agreement, an extension to an existing three-year supply deal, will see Lyndhurst, New Jersey-based Quest running Digene's HPV test, said to be the only FDA-approved test for high-risk types of the cervical cancer-related virus, on the latter's Rapid Capture automated, high-thoroughput analyser.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel